Dr Reddy's Laboratories, an integrated global pharmaceutical company, has re-launched of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).
The re-launch of Dr. Reddy's Naproxen Sodium Tablets, 220 mg (OTC), is an important addition to its Pain/Analgesics portfolio of OTC products.
Dr. Reddy's OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter nonsteroidal anti-inflammatory drug (NSAID) for use as a pain reliever and fever reducer. It temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, menstrual cramps, headache, toothache, and the common cold; it is also used to temporarily reduce fever.
Naproxen Sodium Tablets USP, 220 mg, had U.S. retail sales of approximately USD 316 million as of July 2021 according to IRI. Dr. Reddy's Naproxen Sodium Tablets USP, 220 mg, will be available in multiple-pack sizes to allow consumers a variety of purchasing options.
Shares of the company gained Rs 12, or 0.25%, to settle at Rs 4,783.30. The total volume of shares traded was 68,560 at the BSE (Thursday).